Wang C, Li Q, Xiao B, Fang H, Huang B, Huang F, Wang Y. Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors
IL-24 gene in liver cancer cells.
J Clin Lab Anal 2021;
35:e23677. [PMID:
33274495 PMCID:
PMC7957971 DOI:
10.1002/jcla.23677]
[Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Revised: 11/14/2020] [Accepted: 11/17/2020] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND
Interleukin 24 (IL-24) is an IL-10 family member and a secreted cytokine characterized by cancer-targeted toxicity and can activate apoptosis by sensitizing cancer cells to chemotherapy. Cytotoxic effects of luteolin on different types of cancer cells suppress their growth by acting on the components of the apoptosis signaling cascade. Therefore, our study aimed to prove whether oncolytic vaccinia virus (VV) that harbors IL-24 (VV-IL-24) combine with luteolin exerts a synergistic inhibitory effect in liver cancer cells.
METHODS
Impacts on cell viability of VV-IL-24 and luteolin were assessed by MTT in various liver cancer cell lines. Then, liver cancer cell apoptosis was analyzed via flow cytometry and Western blotting. Besides, the MHCC97-H xenograft mouse model was employed as a means of assessing in vivo antitumor efficacy.
RESULTS
MTT assay confirmed that the combination treatment decreased liver cancer cells viability to a greater degree than treatment with VV-IL-24 or luteolin alone. Flow cytometry and Western blot assay proved that VV-IL-24 plus luteolin induced more liver cancer cells apoptosis than single treatment. Furthermore, in the MHCC97-H xenograft model, 15 days of treatment with VV-IL-24 plus luteolin inhibited tumor growth significantly more than single treatment.
CONCLUSION
These data confirm that the synergistic mechanism of VV-IL-24 and luteolin elicits a stronger tumor growth inhibition than any single therapy. Thus, the combination of VV-IL-24 and luteolin could provide the basis for preclinical research in the treatment of liver cancer.
Collapse